Addex Therapeutics Ltd (ADXN) |
|
1.06 0.02 (1.92%)
|
01-27 16:00 |
|
Open: |
1.08 |
Pre. Close: |
1.04 |
|
High:
|
1.11 |
Low:
|
1.03 |
|
Volume:
|
305,051 |
Market Cap:
|
20(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:42:18 PM |
|
Overall:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
| Target: |
Six months: 1.29  One year: 1.51 |
| Support: |
Support1: 0.76 Support2: 0.55 |
| Resistance: |
Resistance1: 1.11 Resistance2: 1.29 |
| Pivot: |
0.87 |
| Moving Average: |
MA(5): 1 MA(20): 0.82
MA(100): 0.78 MA(250): 2.33 |
| MACD: |
MACD(12,26): 0 Signal(9): 0 |
| Stochastic oscillator: |
%K(14,3): 91.7 %D(3): 94.2 |
| RSI: |
RSI(14): 77 |
| 52-week: |
High: 6.23 Low: 0.55 |
| Average Vol(K): |
3-Month: 185 (K) 10-Days: 228 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ADXN ] has closed below upper band by 6.1%. Bollinger Bands are 90.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 2 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.11 - 1.12 |
1.12 - 1.12 |
|
Low:
|
1.02 - 1.02 |
1.02 - 1.03 |
|
Close:
|
1.05 - 1.06 |
1.06 - 1.07 |
|
Company Description |
|
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland. |
Headline News |
Fri, 27 Jan 2023
Addex Therapeutics Ltd - ADR (ADXN) has risen 7.69% Friday In Premarket Trading - InvestorsObserver
Wed, 18 Jan 2023
Addex Provides Corporate Update and Financial Guidance - Yahoo Finance
Wed, 07 Dec 2022
Addex and Indivior Extend Research Term of Substance Use Disorder GABAB Positive Allosteric Modulator Discovery Collaboration - Yahoo Finance
Thu, 10 Nov 2022
Addex Reports Q3 2022 Financial Results and Provides Corporate Update - Yahoo Finance
Wed, 02 Nov 2022
Addex Therapeutics to Report Third Quarter 2022 Financial Results and Host Conference Call on November 11, 2022 - Yahoo Finance
Tue, 01 Nov 2022
Addex Increases Issued Share Capital to Create Treasury Shares - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
19 (M) |
|
% Held by Insiders
|
4.02e+006 (%) |
|
% Held by Institutions
|
0 (%) |
|
Shares Short
|
110 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.151e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-1 |
|
Return on Assets (ttm)
|
707.4 |
|
Return on Equity (ttm)
|
-87.9 |
|
Qtrly Rev. Growth
|
1.25e+006 |
|
Gross Profit (p.s.)
|
-27.67 |
|
Sales Per Share
|
-124.34 |
|
EBITDA (p.s.)
|
-5.94479e+006 |
|
Qtrly Earnings Growth
|
-3.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-16 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
1.91 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
34860 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
